Recombinant antibodies are monoclonal antibodies produced in vitro using synthetic genes. They are ubiquitous reagents for biological and biochemical research and are rapidly expanding into new therapeutic areas.1
Recombinant antibodies are effective therapeutic treatments for a range of diseases. They are used in the fight against cancer, autoimmune disorders and many others diseases like Covid-19. In addition, recombinant antibodies that recognize specific states of a protein can potentially be used as diagnostic tools.
Like monoclonal antibodies, recombinant antibodies are used for both research purposes and medical applications. More specifically this encompasses the following:
According to specialist publications like the Brazilian Journal of Pharmaceutical2 the production of recombinant monoclonal antibodies has revolutionized the generation of immunoglobulins.
The use of single chain vf antibodies represents a milestone that is affecting the global pharmaceutical market for therapeutic proteins.
While recombinant antibodies are generally used as reagents for biological and biochemical research, they are increasingly seeing new fields of application thanks to their specificity.
Today, thanks to their antigen binding properties and high affinity, recombinant antibodies have become the most common class of therapeutic proteins.
The antibodies produced are used in the treatment of many disease areas including inflammation, immunology and oncology. Recombinant antibodies are applied in the treatment of cancer as well as autoimmune disorders. The application of recombinant antibodies currently plays a major role in the fight against Covid-19.
Antibodies – monoclonal and recombinant as well as polyclonal types – have become mainstays in the biopharmaceutical field. They offer remarkable opportunities for scientific studies and practical development, which is why they are used for a wide field of applications.
Specifically engineered recombinant antibodies can be easily reproduced to an unlimited extent. They are a renewable resource, and the production time of rAbs is weeks versus months for mAbs.
They offer the added benefit of being manipulable so as to match certain predetermined criteria as they can be finetuned by means of antibody engineering. Those antibodies bind against virtually any antigen, including human antigens and toxic molecules.